Skip to content

To understand cardiac and pulmonary function in patients with covid-19 in India

CardiOvaScular and Pulmonary Mechanisms In Covid-19 in India: A multimodality imaging study - COSMIC-INDIA study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030604
Enrollment
100
Registered
2021-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Dr Anoop Shah
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID-19 positive patients 1-COVID-19 positive 2-Ideally 2 weeks withina positive test (but can be extended to 4 weeks) 3-Symptoms suggestive of an acute respiratory viral illness Positive controls 1-COVID-19 negative (PCR andserology) 2-Symptoms suggestive of an acute respiratory viral illness Negative controls 1-COVID-19 negative (PCR andserology) 2-Absence of symptoms of acute respiratory viral illness

Exclusion criteria

Exclusion criteria: 1-Prior diagnosis of myocardial infarction 2-Prior diagnosis of a non-ischaemic cardiomyopathy 3-Patients requiring invasive or non-invasive ventilation 4-Previous coronary revascularisation or cardiac surgery 5-Patient inability to undergo CT or CMR scanning, due to severe renal failure (estimated glomerular filtration rate 6-Pregnancy or breast feeding 7-Inability to give informed consent 8-Contraindication to imaging, example metal fragments in the eye

Design outcomes

Primary

MeasureTime frame
A. Identify the proportion of patients with biochemical evidence of myocardial injury or strain i.Presence of elevated cardiac troponin or NTproBNP concentrations B. Identify the presence of atherosclerotic disease CTCA i.Presence of obstructive coronary artery disease on CTCA 70% C.Identify myocardial disease D.Identify vascular inflammation PET scan E. Describe and quantify degree of pulmonary fibrosis F. Describe the change across cases and positive controlsTimepoint: 6 Months

Secondary

MeasureTime frame
B. Identify the presence of atherosclerotic disease CTCA i.Presence of obstructive coronary artery disease on CTCA 70% C.Identify myocardial disease D.Identify vascular inflammation PET scan E. Describe and quantify degree of pulmonary fibrosis F. Describe the change across cases and positive controlsTimepoint: 6 months

Countries

India

Contacts

Public ContactDr C Narasimhan

AIG Hospital

calambur1@gmail.com9848052409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026